1826
M. M. Abelman et al. / Tetrahedron Letters 44 (2003) 1823–1826
with a methyl substituted maleimide afforded aniline as
the major product (55%) as well as the desired
ketopiperazine (32%) and 13% of a product identified
as the seven-membered ring compound 10 (entry 9).
The latter presumably arises from initial isomerization
of the vinyl methyl group to an exo-methylene moiety
followed by 1,4-addition and ring formation.4
(d) Sharma, S.; Bindra, R.; Iyer, R. N.; Anand, N. J. Med.
Chem. 1975, 18, 913; (e) Cantatore, G.; Borzatta, V. Chem.
Abstr. 1989, 111, 116279n; (f) Gubert, S.; Braojos, C.;
Anglada, L.; Bolos, J.; Sacristan, A.; Ortiz, J. A. J.
Heterocyclic Chem. 1993, 30, 275; (g) Sheremeteva, T. V.;
Kudryavtsev, V. V. Izv. Akad. Nauk SSSR Ser. Khim.
1966, 2, 289.
4. Cave%, C.; Gassama, A.; Mahuteau, J.; d’Angelo, J.; Riche,
In summary we have explored the reaction of substi-
tuted EDAs with various fumarates maleates, citra-
conates and maleimides to form substituted
ketopiperazine acetic acid esters and amides. The chem-
istry is synthetically useful and can yield surprising
results with regard to regio- and stereoselectivity. We
are continuing to explore this reaction in the formation
of various ring sizes using other tethered binucleophiles
(e.g. N,O; S,O; S,N) for application to the medicinal
chemistry of peptidomimetics.
C. Tetrahedron Lett. 1997, 38, 4773.
5. A typical experimental follows for the preparation of
compounds listed in Tables 1 and 2. Compound 5 (Table
2, entry 1): Methyl 2-oxo-3-methyl-3-carboxymethyl-piper-
azine: To a solution of EDA (0.67 mL, 10 mmol) in
methanol (15 mL) at room temperature was added
dimethyl citraconate (1.4 mL, 10 mmol). The reaction was
stirred for 24 h then the methanol was reduced in vacuo to
ca. 25% of its original volume. Ethyl ether was added and
the resulting white precipitate was collected by filtration,
and washed with more ether to afford 1.2 g (65%) of white
1
solid, mp 128–130°C. H NMR (400 MHz, CDCl3) l 1.40
(s, 3H), 2.20 (bs, 1H,), 2.50 (d, J=16.7 Hz, 1H), 3.00 (m,
1H), 3.05 (d, J=16.7 Hz, 1H), 3.12 (ddd, J=13.6, 10.1, 4.3
Hz, 1H), 3.28 (ddd, J=11.7, 7.0, 3.1 Hz, 1H), 3.47 (dddd,
J=11.7, 7.8, 4.68, 1.17 Hz, 1H), 3.65 (s, 3H), 6.02 (bs,
1H); 13C NMR (100 MHz, CDCl3) l 174.3, 172.1, 57.6,
Acknowledgements
We would like to acknowledge the assistance of Betty
Fitzgerald for her expertise in obtaining the requisite
NMR, IR and LC MS spectra. We would also like to
thank Richard Gless, Don James and Paul Baures for
providing thoughtful discussion and insightful com-
ments on the preparation of this manuscript.
51.6, 43.8, 42.8, 38.2, 24.9; IR (KBr) 1718, 1664 cm−1
.
Generally speaking, ketopiperazines with a secondary
amide tended to be solids. The ketopiperazines with a
tertiary amide tended to be oils that were easily purified by
silica gel chromatography using 10% methanol/ethyl ace-
tate as eluent.
6. A typical experimental follows for Table 3. Compound 7
(Table 3, entry 5): 1,4-Dimethyl-2-oxo-3-carboxamide
methyl-piperazine: To a solution of N,N%-dimethyl EDA
(2.1 mL, 20 mmol) in ethanol (30 mL) at room tempera-
ture was added maleimide (1.9 g, 20 mmol). The reaction
was stirred for 24 h and then the ethanol was reduced in
vacuo to ca. 25% of its original volume. Ethyl ether was
added, and the gummy mixture was triturated with a
spatula. After several hours a precipitate formed which
was collected by filtration and washed with more ethyl
ether to afford 3.5 g (95%) of an off-white solid, mp
99–101°C. 1H NMR (400 MHz, CDCl3) l 2.38 (s, 3H),
2.56 (ddd, J=12.47, 10.91, 3.9 Hz, 1H), 2.66 (dd, J=15.6,
5.0 Hz, 1H), 2.85 (dd, J=15.6, 3.5 Hz, 1H), 2.92 (s, 3H),
2.98 (dd, J=4.3, 2.7 Hz, 1H), 3.02 (t, J=5.0 Hz, 1H), 3.12
(dt, J=11.7, 3.6 Hz, 1H), 3.49 (ddd, J=15.6, 11.3, 4.3 Hz,
1H), 5.80 (bs, 1H), 7.00 (bs, 1H); 13C NMR (100 MHz,
CDCl3) l 173.3, 168.3, 64.5, 50.6, 47.3, 43.0, 35.8, 34.5; IR
References
1. (a) Shreder, K.; Zhang, L.; Gleeson, J.-P.; Ericsson, J. A.;
Venkatachalapathi, V. Y.; Goodman, M. J. Comb. Chem.
1999, 1, 383; (b) Dinsmore, C. J.; Bergman, J. M.;
Bogusky, M. J.; Culberson, J. C.; Hamilton, K. A.; Gra-
ham, S. L. Org. Lett. 2001, 3, 865.
2. (a) Petasis, N. A.; Patel, Z. D. Tetrahedron Lett. 2000, 41,
9607; (b) Beshore, D. C.; Dinsmore, C. J. Org. Lett. 2002,
4, 1201; (c) Dinsmore, C. J.; Zartman, C. B. Tetrahedron
Lett. 2000, 41, 6309; (d) Cheng, J.-F.; Chen, M.; Arrhe-
nius, T.; Nadzan, A. Tetrahedron Lett. 2002, 43, 6293; (e)
Gurjar, M. K.; Karmakar, S.; Mohapatra, D. K.; Phal-
gune, U. D. Tetrahedron Lett. 2002, 43, 1897.
3. (a) Phillips, A. P. US Pat. 2,958,693, 1960; Chem. Abstr.
1961, 55, 9437i; (b) Sheremeteva, T. V.; Sharifov, G. S.;
Romashkova, K. A. Dokl. Akad. Nauk SSSR 1968, 182,
859; Chem. Abstr. 1969, 70, 37783d; (c) Masuzawa, K.;
Masaki, M.; Ohta, M. Chem. Pharm. Bull. 1966, 14, 194;
(KBr) 1689, 1633 cm−1
.